Esperion clears merger hurdle as 135 million votes approve Essence deal

Esperion Therapeutics stockholders voted 135 million to 23 million to approve the company's acquisition by Essence Parent Inc., clearing a key hurdle for the merger that will take the biopharmaceutical firm private.

"Stockholders have spoken decisively in favor of this transaction, which we believe maximizes value for shareholders," J. Martin Carroll, chairperson of Esperion's board, said during the virtual special meeting held July 8. Benjamin Looker, the company's chief legal and corporate affairs officer, served as secretary for the meeting.

The merger proposal received 135,326,793 votes in favor, 22,750,628 against and 496,194 abstentions, according to preliminary results announced by Tony Carideo of the Carideo Group, who served as inspector of election. The total represented about 61.5 percent of outstanding shares entitled to vote. Stockholders also approved, on a non-binding advisory basis, merger-related compensation for Esperion's named executive officers, with 129,937,383 votes in favor, 22,283,787 against and 6,352,445 abstentions. The board had recommended voting in favor of both proposals.

The transaction, structured under an Agreement and Plan of Merger dated May 1, 2026, will see Essence MergerCo Inc. merge with Esperion, leaving the company as a wholly owned subsidiary of Essence Parent. The deal includes contingent value rights tied to net sales milestones for Esperion's cholesterol-lowering products, though the total enterprise value and upfront payment structure have not yet been fully disclosed. A quorum was established with holders of a majority of outstanding shares entitled to vote, with a record date of May 28, 2026.

Completion remains subject to customary closing conditions and regulatory approvals, including antitrust clearance. Esperion previously cleared a key U.S. antitrust hurdle for the merger, and the company also gained German approval for the acquisition by ArchiMed, the healthcare-focused private equity firm backing Essence Parent. Esperion said it will report final vote counts in a Form 8-K filing with the Securities and Exchange Commission within four business days of the meeting. The adjournment proposal was not needed because the merger received the required majority support.

The approval comes as Esperion, a clinical-stage biopharmaceutical company focused on oral LDL-C-lowering therapies including NEXLETOL (bempedoic acid), navigates a transition from a publicly traded entity to a private subsidiary. The company's market capitalization stood at about $811.7 million, with average daily trading volume of roughly 13.3 million shares. Esperion's stock trades on the Nasdaq under the ticker ESPR.

For investors, the key remaining questions center on the timing of regulatory clearances and the potential payout from the contingent value rights, which are tied to net sales milestones for Esperion's products. The company's lead therapy, NEXLETOL, an oral adenosine triphosphate-citrate lyase inhibitor approved by the U.S. Food and Drug Administration, targets patients who require additional LDL-C reduction beyond statins or who are statin-intolerant. The cardiovascular therapeutics market represents a significant opportunity, with millions of patients in the U.S. alone who could benefit from alternative or complementary lipid-lowering treatments.

The Esperion deal reflects a broader trend of private equity acquisitions in the biopharmaceutical sector, where companies with approved products but limited commercial scale have become attractive targets. The CVR structure, which ties additional payments to product sales milestones, is a common feature in biotech M&A, allowing buyers to share upside while limiting upfront risk.

The most recent analyst rating on Esperion stock was a Hold with a $3.16 price target, according to TipRanks data. The stock's technical sentiment signal was Buy, reflecting the positive momentum from the merger approval. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways.

This article is for informational purposes only and does not constitute investment advice.